NanoViricides' Antiviral NV-387 Shows Promising Lung Protection in Influenza A Models

NanoViricides, Inc. has announced that its antiviral candidate NV-387 proves effective in protecting lungs from damage in an Influenza A H3N2 mouse model. NV-387 is currently at the Phase II clinical stage.

Anil R. Diwan, President of the company, emphasized the significance of lung protection in severe respiratory infections. NV-387's treatment considerably reduced lung infiltration by immune cells and overall lung damage in infected mice. Oral treatment resulted in 31% infiltration, while intravenous treatment showed only 22%, compared to 68% in untreated animals.

Additionally, NV-387 reduced mucus load in the lungs. The mucus index fell to 53 for oral treatment and 32 for intravenous treatment, from a high of 138 in untreated controls.

NV-387 also improved survival rates in infected animals by 88%, surpassing the performance of approved drugs Oseltamivir, Rapivab, and Baloxavir, which showed a 25-38% improvement.

The treatment showcases promising antiviral activity without the likelihood of viral resistance. NV-387's Phase I trials reported no adverse events, marking it as a safe candidate for further development.